Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 39
Filter
Add more filters










Publication year range
1.
Sci Total Environ ; 916: 170227, 2024 Mar 15.
Article in English | MEDLINE | ID: mdl-38246369

ABSTRACT

Dioxins (PCDD/PCDF) are toxic compounds that are ubiquitous in the environment; although present in low concentrations, they are persistent and highly toxic and they bioaccumulate in food chains. Therefore, it is very important that feed is free of these types of contaminants, because otherwise they can become a source that can negatively affect animal health and the safety of food of animal origin. The aim of the study was to comprehensively assess the concentrations of dioxins and polychlorinated biphenyls (PCBs) in a variety of feed materials available on the Polish market. In addition, characteristic profiles of congeners for given categories of feeds were investigated and defined. Approximately 95 % of the 523 samples of various feed materials tested over seven years (2013-2018 and 2022) met the requirements of European Union feed law (Commission Regulation 277/2012/EU). The highest average PCDD/PCDF/dl-PCB concentrations were found in fish oils and meal and were respectively 1.17 ± 0.78 and 5.51 ± 4.51 ng WHO-TEQ/kg of feed at 12 % moisture. Median and background level concentrations of PCDD/PCDFs, dl-PCBs, PCDD/PCDF/dl-PCBs, and ndl-PCBs were significantly lower than their average concentrations for each individual feed material category. The WHO-TEQ profiles enabled the identification of three different characteristic profiles in feed materials.


Subject(s)
Dioxins , Polychlorinated Biphenyls , Polychlorinated Dibenzodioxins , Animals , Polychlorinated Biphenyls/analysis , Dioxins/analysis , Polychlorinated Dibenzodioxins/analysis , Food Contamination/analysis , Animal Feed/analysis , Dibenzofurans, Polychlorinated
2.
Sci Total Environ ; 903: 166590, 2023 Dec 10.
Article in English | MEDLINE | ID: mdl-37634722

ABSTRACT

This study determines the levels of 49 persistent organic pollutants which were grouped into polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs), polychlorinated biphenyls (PCBs), polybrominated diphenyl ethers (PBDEs), and hexabromocyclododecanes (HBCDDs), in infant formula and varieties of baby food. The analyzed samples (n = 80) came from stores all over Poland. The presence of PCDD/F, PCDD/F/PCB and non dioxin-like (ndl)-PCB congeners above the maximum levels stipulated in Commission Regulation (EU) No 1259/2011 was not detected in any sample. The determined average content of PCDD/Fs/dl-PCBs in the tested baby foods was in the range of 4-10 % of the maximum level, and content of ndl-PCBs was in the range of 2-6 % of the maximum level. Despite these low levels of dioxins, furans, and PCBs, a risk analysis assuming weekly consumption of the recommended food intake showed exceedances of the tolerable weekly intake (TWI). The content of flame retardants was low in all examined categories of food for children and infant formula. The lower-bound concentration of the sum of HBCDD isomers (LB ∑HBCDDs) ranged from below the limit of quantification (LOQ) to 0.0313 ng/g w.w. and the concentration of ∑PBDEs was in a 0.001-1.014 ng/g w.w. range. Neither infant formula nor baby food contributed considerably to infant exposure to HBCDDs or PBDEs. Our research indicates that the safe exposure thresholds for dioxins and PCBs in foods for infants and young children may be too high and perhaps it may be necessary to amend the legislation setting acceptable limits for baby food. It seems reasonable to introduce a recommendation on the frequency of food consumption for children and the control of raw materials for food production, in particular fish and cow milk, should be a permanent control point in the food safety assurance system.

3.
Chemosphere ; 313: 137379, 2023 Feb.
Article in English | MEDLINE | ID: mdl-36436586

ABSTRACT

Dioxins might be introduced into the food chain through a direct or an indirect pathway. The main source of human exposure to dioxins is food of animal origin, whereas feeds are the main route of exposure of farmed animals to dioxins and polychlorinated biphenyls. The aim of the study was to simulate dioxin passage from feed to tissues on farm animals using transfer models, and, in addition, to assess the risk to consumers of food of animal origin. From over 700 feed samples analyzed over the course of 9 years (2013-2021), those exceeding the maximum permissible levels set down in Commission Regulation No 277/2012/EU were selected. These samples being derived from real cases of dioxin contamination made it possible to present the most realistic picture of the effects these feed materials could have had if they had entered the food chain. Three species of animals were selected (laying hens, dairy cattle and slaughter pigs), for which feed materials with dioxin contents exceeding the maximum permissible level were selected in accordance with the nutritional recommendations. The calculated PCDD/PCDF concentrations in chicken eggs, cow's milk and pork were above the maximum permissible level in most cases.


Subject(s)
Dioxins , Polychlorinated Biphenyls , Polychlorinated Dibenzodioxins , Cattle , Animals , Female , Humans , Swine , Dioxins/analysis , Chickens , Food Contamination/analysis , Polychlorinated Dibenzodioxins/analysis , Polychlorinated Biphenyls/analysis , Eggs/analysis , Risk Assessment , Animals, Domestic , Animal Feed/analysis
4.
Environ Pollut ; 317: 120810, 2023 Jan 15.
Article in English | MEDLINE | ID: mdl-36470453

ABSTRACT

The present study reports infants' exposure to fourteen perfluoroalkyl substances (PFASs) in infant formula and baby food. First infant milk, follow-on milk and three types of baby food were analyzed: a variety made of fruits and vegetables, a variety with added fish and one containing meat. The mean lower-bound (LB) concentration of ∑14 PFASs was 0.22 µg/kg wet weight (w.w.) in first infant milk and 0.24 µg/kg w. w. In follow-on milk. Lower levels were noticed in baby food, where the mean LB concentration of ∑14 PFASs was in a 0.019-0.025 µg/kg w. w. Range. Perfluorotetradecanoic acid was found to be in the highest concentration both in baby formula and baby food. Dietary intake of ∑14 PFASs (LB concentration) via infant formula was in 0.3-83.1 ng/kg body weight (b.w.) and 0.3-31.1 ng/kg b. w ranges for first infant milk and follow-on milk respectively. The mean dietary intakes of ∑14 PFASs via one serving of baby food were similar for three varieties and were in a 0.46-0.57 ng/kg b. w. Range. Dietary intake of ∑4 PFASs was negligible in regard to the tolerable weekly intake of 4.4 ng/kg b. w. Recently established by the European Food Safety Authority. This preliminary study brings new information on infant exposure to PFASs in Poland. It is suggested that more sensitive methods be used in the future, and since there are many types of infant foods with different compositions of ingredients, more studies should be conducted.


Subject(s)
Fluorocarbons , Infant Formula , Animals , Infant Food/analysis , Fluorocarbons/analysis , Milk/chemistry , Poland
5.
Chemosphere ; 308(Pt 1): 136243, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36055594

ABSTRACT

Dioxins (PCDD/PCDF) and polychlorinated biphenyls (PCBs) are a group of undesirable chemicals classified as persistent organic pollutants (POPs). The main route of human exposure to these compounds is through the diet (about 80%), with food of animal origin being the predominant source. For this reason, animal feed can contribute significantly to the presence of these compounds in food. The aim of this study was to present the concentrations of dioxins and PCBs as well as congener profiles in feed exceeding the acceptable limits (277/2012/EU). In addition, an attempt was made to identify the source of contamination for the different types of contaminated feedstuffs. Among a total of 743 samples of feed materials from the Polish market tested between 2013 and 2021, exceedances of the maximum levels of dioxins and PCBs were found in 21 samples (2.8%). The largest group among the non-compliant feed samples were feed materials of plant origin (43%) followed in decreasing order by vegetable oils and fats of animal origin (24%), materials of mineral origin (9%), and fish oils and meals (5%). The exceedances of the dioxin limits in the category feed materials of plant origin were only caused by dried materials (pulp, dried alfalfa, dried apple). Furthermore, for 8 (1%) samples, the concentrations of test substances exceeding the Action Levels (AL) were recorded.


Subject(s)
Dioxins , Polychlorinated Biphenyls , Polychlorinated Dibenzodioxins , Animals , Dioxins/analysis , Fish Oils/analysis , Food Contamination/analysis , Humans , Persistent Organic Pollutants , Plant Oils , Polychlorinated Biphenyls/analysis , Polychlorinated Dibenzodioxins/analysis
6.
Int J Cancer ; 94(4): 558-63, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11745444

ABSTRACT

Human kallikrein 2 (hK2) is a secreted, trypsin-like protease that shares 80% amino acid sequence identity with prostate-specific antigen (PSA). hK2 has been shown to be a serum marker for prostate cancer and may also play a role in cancer progression and metastasis. We have previously identified a novel complex between human kallikrein 2 (hK2) and protease inhibitor 6 (PI-6) in prostate cancer tissue. PI-6 is an intracellular serine protease inhibitor with both antitrypsin and antichymotrypsin activity. In the current study we have shown that PI-6 forms a rapid in vitro complex with hK2 but does not complex with PSA. Recombinant mammalian cells expressing both hK2 and PI-6 showed hK2-PI-6 complex in the spent media only after cell death and lysis. Similarly, LNCaP cells expressing endogenous hK2 and PI-6 showed extracellular hK2-PI-6 complex formation concurrently with cell death. Immunostaining of prostate cancer tissues with PI-6 monoclonal antibodies showed a marked preferential staining pattern in cancerous epithelial cells compared with noncancerous tissue. These results indicate that the hK2-PI-6 complex may be a naturally occurring marker of tissue damage and necrosis associated with neoplasia. Both hK2 and PI-6 were shed into the lumen of prostate cancer glands as granular material that appeared to be cellular necrotic debris. The differential staining pattern of PI6 in tissues suggests a complex regulation of PI-6 expression that may play a role in other aspects of neoplastic progression.


Subject(s)
Prostate-Specific Antigen/chemistry , Prostate-Specific Antigen/metabolism , Prostatic Neoplasms/metabolism , Serpins/chemistry , Serpins/metabolism , Tissue Kallikreins/chemistry , Tissue Kallikreins/metabolism , Antibodies, Monoclonal/metabolism , Blotting, Western , Cells, Cultured , Cloning, Molecular , Disease Progression , Humans , Immunohistochemistry , Male , Necrosis , Prostate/metabolism , Prostatic Neoplasms/diagnosis , Protein Binding , Recombinant Proteins/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Time Factors , Tumor Cells, Cultured
7.
Cancer Res ; 61(18): 6958-63, 2001 Sep 15.
Article in English | MEDLINE | ID: mdl-11559576

ABSTRACT

Prostate-specific antigen (PSA) is a widely used serum marker for prostate cancer (PCa) but has limited specificity for distinguishing early PCa from benign prostatic hyperplasia, because both PCa and benign prostatic hyperplasia release PSA into the serum. We have identified previously a truncated form of precursor PSA (pPSA) in prostate tumor extracts consisting of PSA with a serine-arginine pro leader peptide ([-2]pPSA) instead of the normally expressed 7 amino acid pro leader peptide. In the current study we developed monoclonal antibodies to detect [-2]pPSA and other isoforms of pPSA for Western blot analysis. PSA was immunoaffinity purified from 100 to 200 ml of serum from each of five men with biopsy-proven cancer and three biopsy-negative men, all with total PSA levels in the diagnostically relevant range near 10 ng/ml. The truncated [-2]pPSA was estimated to range from 25 to 95% of the free PSA in the five PCa samples but only 6-19% of the free PSA in the biopsy-negative men. Immunohistochemical studies showed positive staining for [-2]pPSA in PCa epithelium and that [-2]pPSA was enriched in cancer cell secretions. In vitro activation studies showed that human kallikrein 2 and trypsin readily activated full-length pPSA but were unable to activate [-2]pPSA to mature PSA. Thus, [-2]pPSA, once formed, is a stable but inactive isoform of PSA. Truncated [-2]pPSA may represent an important new diagnostic marker for the early detection of PCa.


Subject(s)
Prostate-Specific Antigen/blood , Prostatic Neoplasms/blood , Protein Precursors/blood , Amino Acid Sequence , Animals , Antibodies, Monoclonal , Antibody Specificity , Biopsy , Cricetinae , Humans , Immunohistochemistry , Male , Prostate-Specific Antigen/immunology , Prostatic Neoplasms/immunology , Prostatic Neoplasms/pathology , Protein Isoforms , Protein Precursors/immunology
8.
Clin Chem ; 47(7): 1218-24, 2001.
Article in English | MEDLINE | ID: mdl-11427452

ABSTRACT

BACKGROUND: Human kallikrein 2 (hK2) shares 80% sequence identity with prostate-specific antigen (PSA). Because both hK2 and hK2-alpha(1)-antichymotrypsin (hK2-ACT) complexes have been identified in patient sera, we devised an immunoassay for total hK2 [(thK2); hK2 and hK2-ACT] and evaluated it in healthy subjects and patients with prostate disease. METHODS: We developed monoclonal antibodies (mAbs) with high specificity for hK2 and hK2-ACT and minimal cross-reactivity to PSA. Using these mAbs, a sandwich assay was developed and its specificity for forms of hK2 was assessed. Serum samples (n = 1035) from healthy volunteers, patients with increased PSA, and men who had undergone radical prostatectomy were assayed for thK2. We also measured thK2 in samples before and after storage under common laboratory conditions. RESULTS: The minimum detectable concentration in the thK2 assay was 0.008 microg/L, and PSA cross-reactivity was <0.001%. The assay detected prohK2 and three different hK2-serum protease complexes. The median serum concentration of thK2 in control samples (0.013 microg/L) was significantly lower than the median in samples from patients with increased PSA concentrations (0.085 microg/L). Immunoreactive hK2 changed little in samples stored for up to 1 month at -70 degrees C. CONCLUSIONS: The thK2 assay recognizes all forms of hK2 that have been found in bodily fluids to date.


Subject(s)
Antibodies, Monoclonal , Tissue Kallikreins/blood , Blood Specimen Collection , Cross Reactions , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Prostate-Specific Antigen/blood , Prostatic Diseases/blood , Sensitivity and Specificity , Tissue Kallikreins/immunology
9.
Prostate ; 45(3): 271-6, 2000 Nov 01.
Article in English | MEDLINE | ID: mdl-11074531

ABSTRACT

BACKGROUND: We previously reported that levels of BPSA, a modified form of prostate-specific antigen (PSA), are significantly elevated in prostate transition-zone tissue exhibiting nodular hyperplastic changes associated with the presence of benign prostatic hyperplasia (BPH). BPSA was purified and found to contain a characteristic clip between Lys182 and Ser183. We now describe the identification of BPSA in seminal plasma. METHODS: PSA was purified from seminal plasma by immunoaffinity chromatography. The purified PSA was further resolved by hydrophobic interaction chromatography, and the individual PSA forms were analyzed by gel electrophoresis and N-terminal amino-acid sequencing. RESULTS: BPSA comprised about 8% of the PSA in pooled seminal plasma, and was identical to BPSA purified from prostate tissues. BPSA was cleanly resolved from all active and inactive forms of PSA. Other inactive forms of PSA in seminal plasma consisted largely of PSA clipped at Lys145, though about 30% of the inactive seminal plasma PSA was intact, mature PSA. CONCLUSIONS: BPSA represents a distinct form of inactive PSA in the seminal plasma that may represent a specific marker for the biochemical changes associated with nodular development in the prostate transition zone found in patients with BPH.


Subject(s)
Prostate-Specific Antigen/analysis , Prostatic Hyperplasia/immunology , Biomarkers/analysis , Electrophoresis, Agar Gel , Humans , Male , Prostate-Specific Antigen/immunology , Prostatic Hyperplasia/physiopathology , Semen/immunology , Sequence Analysis, Protein
10.
Prostate ; 44(3): 248-54, 2000 Aug 01.
Article in English | MEDLINE | ID: mdl-10906742

ABSTRACT

BACKGROUND: Human prostate-specific antigen (PSA) and human kallikrein 2 (hK2) are expressed primarily by prostate epithelial cells. PSA and hK2 both exist as free protein and complexed with protease inhibitors (e.g., alpha1-antichymotrypsin, ACT) in serum. The expression of PSA and hK2 in LNCaP cells is upregulated by androgen. METHODS: LNCaP, a prostate cancer cell line that secretes both PSA and hK2, was used as a model to study the biosynthesis and processing of PSA and hK2 upon androgen induction. RESULTS: Precursor (zymogen or pro) forms of both PSA and hK2 were detected in spent media of induced and noninduced LNCaP cells, indicating that PSA and hK2 are secreted as proPSA (pPSA) and prohK2 (phK2), respectively, and are converted to the mature forms extracellularly. A 3-fold higher ratio of mature to pPSA was detected in the spent media of mibolerone-induced LNCaP cells compared to noninduced cells. In addition to the inactive proform of PSA, more than half of the mature unclipped PSA present in the spent media did not complex with exogenously added ACT. Spent media of mibolerone-induced LNCaP cells contained nearly 100% mature hK2, whereas the spent media of noninduced cells contained mostly phK2. CONCLUSIONS: These results indicate that androgens not only upregulate the expression of these kallikreins, but also have a significant effect on the processing of PSA and hK2. These results also show that LNCaP cells express a heterogeneous mixture of inactive PSA and hK2 forms that may serve as a model for the genesis of these forms in physiological fluids. These findings may also provide insights into the forms and ratios of PSA and hK2 in normal and malignant breast tissues.


Subject(s)
Gene Expression Regulation, Neoplastic , Nandrolone/analogs & derivatives , Prostate-Specific Antigen/biosynthesis , Prostatic Neoplasms/enzymology , Testosterone Congeners/pharmacology , Tissue Kallikreins/biosynthesis , Antibodies, Monoclonal , Chromatography, Affinity , Chromatography, High Pressure Liquid , Humans , Male , Nandrolone/pharmacology , Prostate/enzymology , Prostate-Specific Antigen/analysis , Prostate-Specific Antigen/genetics , Prostatic Neoplasms/chemistry , Prostatic Neoplasms/genetics , Protein Isoforms , Sequence Analysis, Protein , Tissue Kallikreins/analysis , Tissue Kallikreins/genetics , Tumor Cells, Cultured , alpha 1-Antichymotrypsin/chemistry
11.
Eur J Biochem ; 267(13): 4040-5, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10866804

ABSTRACT

We previously identified a modified molecular form of prostate-specific antigen that is significantly elevated in the nodular transition zone tissue of prostates with benign prostatic hyperplasia. This prostate-specific antigen form, designated BPSA, is inactive and contains clipped polypeptide bonds at amino-acid residues Lys145-146 and Lys182-183. BPSA is not elevated in prostate cancer tissues and may therefore be a prostate-specific antigen marker to better discriminate benign prostatic hyperplasia from early prostate cancer. In this work we characterize the immunoreactivity of BPSA in competition assays with prostate-specific antigen using anti-prostate-specific antigen mAb recognizing six different epitopes on the prostate-specific antigen molecule. One mAb showed > 50% loss of immunoreactivtiy with BPSA compared with prostate-specific antigen, while the binding of two mAbs was largely unaffected and three mAbs had intermediate reactivity. BPSA purified from prostate tissue and seminal plasma, as well as BPSA generated in vitro by mild trypsin-treatment were found to have a similar pattern of reactivity to the six mAbs. However, other forms of inactive seminal plasma prostate-specific antigen, either intact or clipped at Lys145 only, had immunoreactivity similar to total prostate-specific antigen. These results demonstrate that BPSA has unique immunological properties from other forms of prostate-specific antigen, which should allow the development of BPSA-specific mAbs for the study of benign prostatic hyperplasia. Measurement of BPSA levels in the serum may help discriminate benign prostatic hyperplasia from early prostate cancer.


Subject(s)
Antibodies, Monoclonal/immunology , Prostate-Specific Antigen/immunology , Prostatic Hyperplasia/immunology , Animals , Epitopes , Humans , Male , Mice , Prostatic Hyperplasia/diagnosis , Semen/immunology , Trypsin/pharmacology
12.
Cancer Res ; 60(3): 756-9, 2000 Feb 01.
Article in English | MEDLINE | ID: mdl-10676664

ABSTRACT

Prostate-specific antigen (PSA) is a widely used serum marker for prostate cancer (PCa), but in the critical diagnostic range of 4-10 ng/ml it has limited specificity for distinguishing early PCa from benign prostatic hyperplasia (BPH). PSA in serum is comprised of a variety of both "free" and "complexed" forms that have been used to improve the specificity of PSA for prostate cancer detection. We previously reported that pro PSA (pPSA), the zymogen or precursor form of PSA, is a component of free PSA in the serum of PCa patients. In the current study, we examined prostate tissues to understand the origin and specificity of pPSA. PSA was immuno-affinity purified from matched sets of prostate tissues including peripheral zone cancer (PZ-C); peripheral zone noncancer; and benign tissue from the transition zone (TZ), the primary site of BPH within the prostate. We found that pPSA is differentially elevated in PZ-C, but is largely undetectable in TZ. N-terminal sequencing revealed that the pPSA was comprised primarily of [-2]pPSA and minor levels of [-4]pPSA, containing pro leader peptides of 2 and 4 amino acids, respectively. The median value of pPSA was 3% in PZ-C and 0% (undetectable) in TZ (P < 0.0026). No pPSA was detected in 13 of 18 transition zone specimens (72%), but only 2 of the 18 matched cancer specimens (11%) contained no measurable pPSA. These results demonstrate that pPSA is more highly correlated with prostate cancer than with BPH. The pPSA in serum may represent a more cancer-specific form of PSA that could help distinguish prostate cancer from BPH.


Subject(s)
Prostate-Specific Antigen/biosynthesis , Prostate/metabolism , Prostatic Hyperplasia/metabolism , Prostatic Neoplasms/metabolism , Protein Precursors/biosynthesis , Humans , Male
13.
Urology ; 55(1): 41-5, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10654892

ABSTRACT

OBJECTIVES: The biologic mechanism for the increased proportion of noncomplexed ("free") prostate-specific antigen (PSA) found in the serum of patients with benign prostate disease is unknown. We recently reported that most of the PSA found in benign, hyperplastic, and cancerous prostatic tissue is in the free form. To determine whether specific molecular forms of free PSA are associated differentially with normal, hyperplastic, or cancerous prostatic tissue, we have further characterized the free PSA in each type of prostatic tissue. METHODS: PSA was purified by immunoaffinity chromatography from matched prostatic tissue samples of peripheral zone cancer (PZ-C), PZ noncancer (PZ-N), and transition zone (TZ) tissue from 10 large-volume (greater than 50 g) and 8 small-volume (less than 25 g) radical prostatectomy specimens. Eight TZ specimens obtained during transurethral resection of the prostate for benign prostatic hyperplasia (BPH) were also analyzed. The different molecular forms of PSA were further resolved by high-performance hydrophobic interaction chromatography. Clipped forms of PSA were identified by N-terminal amino acid sequencing. RESULTS: More than 99% of the PSA in prostatic tissues was in the free, noncomplexed form. Specimens from the prostate TZ were found to contain elevated levels of an altered form of PSA, which we designated BPSA. Purified BPSA contained a distinctive cleavage at lysine 182. The median percent BPSA (%BPSA) was 11.4 in the TZ of specimens with nodular BPH compared with a %BPSA of 4.1 in the TZ of specimens without nodular BPH (P <0.0014). The median %BPSA levels of the PZ-N and PZ-C tissues ranged from 3.2 to 4.9 and were not significantly different from one another or from the %BPSA level of TZ tissues without nodular BPH. CONCLUSIONS: We have identified a specific molecular form of clipped free PSA, called BPSA, that is increased within the prostatic TZ of patients exhibiting nodular BPH. Higher levels of percent free PSA in serum have been found to correlate strongly with prostate volume, which in turn is closely associated with the progressive enlargement of nodular BPH tissue within the TZ of the prostate. Thus, it is possible that a proportion of the serum percent free PSA found in patients with BPH may be composed of BPSA released into the serum.


Subject(s)
Prostate-Specific Antigen/analysis , Prostate/chemistry , Prostatic Hyperplasia/metabolism , Humans , Male , Prostate/metabolism , Prostate-Specific Antigen/biosynthesis
14.
Cancer Res ; 59(16): 3927-30, 1999 Aug 15.
Article in English | MEDLINE | ID: mdl-10463585

ABSTRACT

Human kallikrein (hK) 2 is an arginine-selective serine protease expressed predominantly in the prostate that has an 80% sequence identity with prostate-specific antigen. Expression of hK2 is elevated in the tumor epithelium compared to benign prostate tissue. We have purified, sequenced, and identified a novel hK2 complex in prostate tissue consisting of hK2 and a serine protease inhibitor known as protease inhibitor-6 (PI-6). This 64-kDa SDS-PAGE stable complex is elevated in the tumor and is approximately 10% of total hK2. No comparable complex of prostate-specific antigen was detected. PI-6, also known as cytoplasmic antiprotease, has been characterized as an intracellular inhibitor of trypsin and chymotrypsin-like proteases, which has high homology to plasminogen activator inhibitor 1 and 2. The physiological role of PI-6 in the prostate and its relationship to hK2 and prostate cancer are under investigation.


Subject(s)
Kallikreins/metabolism , Prostatic Neoplasms/metabolism , Serpins/metabolism , Biomarkers, Tumor , Cytoplasm/metabolism , Humans , Male , Prostatic Neoplasms/pathology , Protein Binding , Serine Proteinase Inhibitors/metabolism , Tissue Kallikreins
15.
Int J Cancer ; 81(3): 438-42, 1999 May 05.
Article in English | MEDLINE | ID: mdl-10209959

ABSTRACT

Human kallikrein 2 (hK2) is a serine protease expressed predominantly in the prostate which has 80% homology to prostate-specific antigen (PSA). hK2 is an active trypsin-like protease which has been shown by immuno-histochemical staining to be more highly expressed in prostate carcinoma than in benign prostate tissue. Unlike PSA, hK2 activates pro-PSA , pro-hK2 and the zymogen form of urokinase-type plasminogen activator (uPA), an extracellular protease correlated with prostate cancer and metastasis. We show here that hK2 rapidly forms a complex with plasminogen activator inhibitor-1 (PAI-1), the primary inhibitor of uPA in tissues. In addition, hK2 inactivated 6 to 7 mol of PAI-1 by cleavage at Arg346-Met347 for every mole of hK2-PAI-1 complex formed. In contrast with hK2, PSA neither complexed with nor inactivated PAI-1. PAI-1 inhibited hK2 comparably with protein C inhibitor (PCI) and at least 20 times more rapidly than alpha1-anti-chymotrypsin (ACT). N-Terminal sequencing shows that hK2 forms a covalent complex with PAI-1, PCI and ACT after cleavage at Arg346-Met347, Arg354-Ser355 and Leu358-Ser359, respectively. During complex formation, hK2 inactivated PAI-1 but did not inactivate ACT or PCI. Our current results suggest that the increased hK2 expression in prostate cancer tissues could influence cancer biology not only by activation of uPA but also by inactivation of its primary inhibitor, PAI-1.


Subject(s)
Kallikreins/physiology , Plasminogen Activator Inhibitor 1/metabolism , Prostate/enzymology , Humans , Kallikreins/antagonists & inhibitors , Male , Plasminogen Activator Inhibitor 1/pharmacology , Prostate-Specific Antigen/antagonists & inhibitors , Prostatic Neoplasms/enzymology , Protein C/antagonists & inhibitors , Urokinase-Type Plasminogen Activator/metabolism , alpha 1-Antichymotrypsin/pharmacology
16.
Protein Expr Purif ; 15(1): 62-8, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10024471

ABSTRACT

Human glandular kallikrein 2 (hK2) is a trypsin-like serine protease that is expressed predominantly in the prostate epithelium and has 78% aa identity with prostate-specific antigen (PSA). hK2 has been recognized as a potential prostate cancer marker and has been demonstrated to be highly expressed in prostate cancer compared to benign prostatic tissue. Purification and characterization of hK2 have been impeded due to its lower expression in bodily fluids and tissues compared to PSA and its ability to autodegrade. Therefore, to study biochemical and biological characteristics of hK2, a stable and enzymatically inactive mutant form of hK2, hK2(A217V), was expressed in a hamster cell line, AV12-664 (AV12-hK2(A217V)). AV12-hK2(A217V) cells secreted prohK2(A217V) (phK2(A217V)) in the spent medium at approximately 2.5 microgram/ml. Since AV12-hK2(A217V) are adherent cells, it was necessary to develop an efficient system to propagate large numbers of cells to obtain significant quantities of phK2(A217V). In this paper, we compared ceramic core bioreactor and microcarrier beads as alternatives to static culture to propagate adherent cells. Considering production levels, ease of operation, cost effectiveness, and labor, microcarrier beads were found to be a better alternative. Our findings led to the development of a general protocol for large-scale propagation of adherent cells on microcarrier beads eliminating the need for propagating AV12-hK2(A217V) in culture flasks or bioreactors. Microcarrier beads coated with AV12-hK2(A217V) cells could be propagated in 1- or 3-liter spinner flasks and were passed from one spinner to the next in a manner analogous to static culture or could be frozen and later used as inoculum for subsequent spinners. Using this protocol, >40 liters of spent medium was harvested within 30 days, which in turn was used to purify phK2(A217V). phK2(A217V) purified from spent medium of cells grown either on microcarrier beads or in culture flasks were biochemically similar as indicated by HIC-HPLC profile followed by sequencing of relevant peaks.


Subject(s)
Kallikreins/biosynthesis , Animals , Bioreactors , Blotting, Western , Cell Adhesion , Cell Culture Techniques/instrumentation , Cell Culture Techniques/methods , Cell Line , Ceramics , Cricetinae , Enzyme-Linked Immunosorbent Assay , Humans , Kallikreins/genetics , Kallikreins/metabolism , Polymerase Chain Reaction , Promoter Regions, Genetic , Recombinant Proteins/biosynthesis , Recombinant Proteins/metabolism , Tissue Kallikreins , Transfection/methods
17.
Crit Rev Clin Lab Sci ; 35(4): 275-368, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9759557

ABSTRACT

Recent studies on human kallikrein 2 (hK2) have revealed striking similarities and significant differences with the closely related kallikrein PSA. Both PSA and hK2 are primarily localized to the prostate and share close structural similarities. Although both kallikreins are produced by the same secretory epithelial cells in the prostate, hK2 is associated more with prostate tumors than PSA and is highly expressed in poorly differentiated cancer cells. The potent trypsin-like activity of hK2 contrasts with the weak chymotrypsin-like activity of PSA. The inactive precursor form of PSA, proPSA, is converted rapidly to active PSA by hK2, suggesting an important in vivo regulatory function by hK2 on PSA activity. The high homology between hK2 and PSA results in significant cross-reactivity to hK2 by polyclonal and some monoclonal antibodies to PSA. Future studies on both PSA and hK2 need to take into account this potential for cross-reactivity. Specific monoclonal antibodies to hK2 have now demonstrated that serum levels of hK2, like PSA, are correlated with prostate cancer. The production of hK2 protein in active protease form and specific monoclonal antibodies to the hK2 antigen will allow extensive future studies delineating the physiological and clinical utility of this new prostate antigen.


Subject(s)
Kallikreins/metabolism , Prostate-Specific Antigen/metabolism , Prostate/chemistry , Vasoconstrictor Agents/metabolism , Humans , Kallikreins/analysis , Kallikreins/genetics , Male , Molecular Sequence Data , Prostate-Specific Antigen/analysis , Prostate-Specific Antigen/genetics , Prostatic Neoplasms/metabolism , Sequence Homology, Amino Acid , Tissue Kallikreins , Vasoconstrictor Agents/analysis
18.
Clin Chem ; 44(10): 2115-9, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9761243

ABSTRACT

Prostate-specific antigen (PSA, hK3) is a diagnostic marker for prostatic cancer but lacks the specificity to sufficiently distinguish between prostatic cancer and benign prostatic hyperplasia (BPH). Human glandular kallikrein 2 (hK2) has been proposed as a potential diagnostic marker for prostate cancer that could complement the current PSA test. Recently we demonstrated that proPSA is present in prostate cancer sera. This study examines the expression of prohK2 in prostate cells and its presence in human sera. Western blot analysis was used to assess prohK2 expression in the human carcinoma cell line, LNCaP. A highly specific and sensitive dual monoclonal immunoassay for prohK2 was developed and used to assess the presence of prohK2 in human sera. prohK2 was detected in the spent media of LNCaP cells. Furthermore, prohK2 was present at immunodetectable concentrations in human sera, and its concentration was increased in prostatic cancer and BPH. These results indicate for the first time that prohK2 is secreted by human prostate cells and is a major component of uncomplexed (free) hK2 in human sera. In addition, prohK2 in human sera is associated with prostate disease and thus may be a useful marker for prostatic cancer and BPH.


Subject(s)
Biomarkers, Tumor/blood , Prekallikrein/analysis , Prostate-Specific Antigen/blood , Prostatic Hyperplasia/blood , Prostatic Neoplasms/blood , Antibodies, Monoclonal/immunology , Blotting, Western , Humans , Immunoassay , Male , Prekallikrein/biosynthesis , Prekallikrein/immunology , Prostatic Hyperplasia/metabolism , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Sensitivity and Specificity , Tumor Cells, Cultured
19.
J Androl ; 19(4): 407-11, 1998.
Article in English | MEDLINE | ID: mdl-9733142

ABSTRACT

Forms of human glandular kallikrein (kK2) in prostate carcinoma serum were identified using monoclonal antibodies specific for hK2 and prohK2. Recombinant mammalian hK2, prohK2, and prostate = specific antigen (PSA) were utilized to confirm the specificity of monoclonal antibodies for hK2 and the lack of reactivity with PSA. In prostate cancer patient sera containing high levels of hK2 (>100 ng/ml), hK2 exists as a complex with alpha1-antichymotrypsin with a molecular weight of 90 kDa. The kallikrein also exists as a 32-kDa free form, which includes the precursor pro form of hK2. The relative amount of complex and free hK2 varied, but in most sera examined the 32-kDa form predominated. Recombinant hK2 readily formed complexes with alpha2-macroglobulin when the two proteins were incubated together as well as when hK2 was spiked into female serum.


Subject(s)
Kallikreins/analysis , Prostatic Neoplasms/blood , Antibodies, Monoclonal , Blotting, Western , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoradiometric Assay , Male
20.
Urology ; 51(5): 804-9, 1998 May.
Article in English | MEDLINE | ID: mdl-9610595

ABSTRACT

OBJECTIVES: Human glandular kallikrein (hK2) is a protein that is 80% homologous to prostate-specific antigen (PSA), and, like PSA, is localized to the prostate. We developed a specific immunoassay for hK2 that can be used to evaluate its clinical diagnostic utility. METHODS: We developed monoclonal antibodies (mAbs) specific for hK2 by immunizing with hK2 and screening for clones reactive with hK2 and not PSA. Prototype sandwich assays using these mAbs were tested, and the optimum pair selected. Purified hK2 was used as standard and PSA cross-reactivity was assessed in the assay. Both hK2 and hK2-alpha1-antichymotrypsin (ACT) complexes have been identified in sera of patients with prostate cancer (PCa). Serum samples (n = 671) from healthy volunteers and patients with prostate disease were assayed for hK2 and PSA levels. RESULTS: The assay had a detection limit of less than 0.12 ng/mL and a less than 0.5% cross-reactivity with PSA. The assay preferentially detected free hK2 with a 3.5-fold higher molar response than with hK2-ACT. The mean serum concentration of hK2 in normal control samples was low (0.33 and 0.37 ng/mL for normal healthy men and women, respectively) but was elevated in patients with prostate disease (0.86 and 6.77 ng/mL for patients with benign prostatic hyperplasia and PCa, respectively). Negligible cross-reactivity to hK2 was measured by Tandem PSA assays (Hybritech). CONCLUSIONS: Significant concentrations of hK2, relative to PSA, were detected in human serum, especially in patients with prostate disease. Serum hK2 concentrations were not proportional to PSA concentration. Therefore, hK2 has the potential to be an independent and clinically useful marker for PCa.


Subject(s)
Antibodies, Monoclonal , Immunoassay/methods , Kallikreins/analysis , Biomarkers/analysis , Biomarkers/blood , Biomarkers, Tumor/analysis , Biomarkers, Tumor/blood , Cross Reactions , Enzyme-Linked Immunosorbent Assay , Female , Humans , Kallikreins/immunology , Male , Prostate-Specific Antigen/immunology , Prostatic Diseases/blood , Prostatic Hyperplasia/blood , Prostatic Neoplasms/blood , Semen/chemistry , alpha 1-Antichymotrypsin/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...